查询词典 monoblastic

AIM: To investigate the effects of artemisinin on apoptosis and differentiation of classic human acute monoblastic leukemia cell line U937 and to study the possibility of treatment of leukemia with artemisinin.

目的：通过青蒿素对经典人白血病细胞系U937的作用研究，探索青蒿素治疗白血病的可能。

Chk1 is one of the major checkpoint gene involved in G2/M checkpoint, as well as involved in G1/S and Intra S arrest. We use U937 human monoblastic leukemia cell as a model to study human Chk1 RNA isoforms and transcription regulation.

Checkpoint 的功用为侦测细胞内DNA damage的发生，并藉由阻止细胞周期的进行，提供细胞足够的时间修复错误，Chk1即为其中的一种重要的基因。

In vitro, studies demonstrated that new retinoids in combination with IFN-γ could induce monoblastic leukemia cells to differentiate and inhibit their proliferention.

本文研究了NB4细胞株和新鲜急性早幼粒白血病细胞在新维甲类R9158、R8923、R9123和YS904012作用后的生物学特性变化；并且在初筛的基础上，选用R9158和YS904012与IFN-γ联合使用，研究对U937细胞株和6例原代单核系白血病细胞的增殖分化作用。

Methods We used Amphotericin B for fungous septicemia complicated with allo-geneic hematopoietic stem cell transplantation (2 cases of server aplastic anemia, 1 case of acute lymphoblastic leukemia) or chemotherapy (2 cases of chronic lymphoblastic leukemia,5 cases of acute monoblastic leukemia). The long-term of one to three months Amphotericin B was used at total dose range from 1750 to 3115 microgram with drug prophylaxis and care.

对异基因造血干细胞移植3例（SAA 2例、ALL 1 例）和白血病化疗后7例（CLL 2例、M55例），出现真菌性败血症时应用长程（1～3个月）的两性霉素B治疗，总剂量为1750～3115 mg，观察其疗效和并发症，且对并发症采用药物预防和护理。

Results Twenty-seven cases (12.8%) were MK antigen positive with the higher positive rates in hybrid acute leukemia(45.5%) and acute monoblastic leukemia(24.1%).

结果 27例(12.8%)表达MK；AML亚型中以杂合急性白血病和急性单核细胞白血病（M5）表达最高，分别为45.5%和24.1%。

In Vitro study on the impact of overexpression of RbAp46 in U937cell lineObjective To study the impact of overexpression of RbAp46 in monoblastic cell line U937. Methods Viability of transfected cells was assayed by trypan blue exclusion.Cell number was counted daily to determine the growth rate.

将处在对数生长期U937／RbAp46和U937／CMV各以2×10~5／ml浓度接种，加入TPA50ng／ml，同时并以培养基作为空白对照，培养72小时后收集细胞，流式细胞术测定细胞表面分化抗原CD11b的表达，RT-PCR分析p21mRNA的表达，流式细胞术检测细胞周期分布情况。

2B8a was weakly reactive to neutrophils (23.72%) and negative for T cells, NK, DC, RBC and Plt. The antibody reacted to all 3 marrow CD34+ cells with an average positive rate of 39.33% while it was negative for G-CSF-mobilized CD34+ peripheral blood stem/progenitor cells (PBSC, 1.25%). Cell line analysis showed that the antibody notably reacted to three out of 4 cell lines (Raji, SMS-SB, Nalm-6 and Nall-1) with the positive rates of 98.78%, 98.61%, 94.93% respectively and weakly to one of them with 5.68% in B lineage cell lines and monoblastic cell line (U937, 67.78%) while it was only weakly positive or negative for other myeloid leukemia cell lines including Meg01 (33.40%), HL-60 (29.70%),K562 (28.19%), KG1a (16.23 %) and HEL92.1.7 (8.02%). Among 4 T lineage leukemia,5 neuroblastoma and 1 colon cancer cell lines tested, only Molt-3 was found weakly positive (31.40%) for 2B8a, while the remaining 3 T cell lines (Molt4, JM and CCRF-CEM), 5 neuroblastoma cell lines (LA-N1, KCNR, BE, SK-N-SH, SK-N-AS) and the colon cancer cell line (HR8348) tested were negative.

结果表明： 2B8a抗原在外周血B细胞上表达（3/3例，平均阳性细胞数为26.29 ％），而在T淋巴细胞和NK细胞上不表达（0/3例）；在粒细胞和单核细胞上阳性表达均为2/3例，平均阳性细胞数分别是23.72 ％和59.84 ％；在DC细胞、红细胞和血小板上均不表达（0/3例）。2B8a抗原在骨髓CD34＋细胞上的阳性表达是3/3例，平均阳性细胞数39.33 ％，而在G-CSF动员的外周血CD34+细胞上的阳性表达仅1/3例，平均阳性细胞数为1.25 ％。2B8a抗原在B系细胞系Raji、SMS-SB、Nalm-6和Nall-1上的平均阳性细胞数分别为98.78 ％、98.61 ％、94.93 ％和5.68 ％；在T系细胞系Molt-3上的平均阳性细胞数为31.40 ％，而在Molt-4、JM和CCRF-CEM 细胞上不表达；在髓系细胞系U937、Meg-01、HL-60、K562、KG1a和HEL92.1.7上的平均阳性细胞数分别为67.78 ％、33.40 ％、29.70 ％、28.19 ％、16.23 ％和8.02 ％；在神经母细胞瘤细胞系SK-N-SH、KCNR、BE、LAN-1和SK-N-AS细胞以及结肠癌细胞系HR8348细胞上均不表达，而在羊膜细胞系FL细胞上呈一定的阳性表达，平均阳性细胞数为45.03％。

Cell line analysis showed that the antibody notably reacted to three out of 4 cell lines (Raji, SMS-SB, Nalm-6 and Nall-1) with the positive rates of 98.78%, 98.61%, 94.93% respectively and weakly to one of them with 5.68% in B lineage cell lines and monoblastic cell line (U937, 67.78%) while it was only weakly positive or negative for other myeloid leukemia cell lines including Meg01 (33.40%), HL-60 (29.70%),K562 (28.19%), KG1a (16.23 %) and HEL92.1.7 (8.02%). Among 4 T lineage leukemia,5 neuroblastoma and 1 colon cancer cell lines tested, only Molt-3 was found weakly positive (31.40%) for 2B8a, while the remaining 3 T cell lines (Molt4, JM and CCRF-CEM), 5 neuroblastoma cell lines (LA-N1, KCNR, BE, SK-N-SH, SK-N-AS) and the colon cancer cell line (HR8348) tested were negative.

结果表明： 2B8a抗原在外周血B细胞上表达（3/3例，平均阳性细胞数为26.29 ％），而在T淋巴细胞和NK细胞上不表达（0/3例）；在粒细胞和单核细胞上阳性表达均为2/3例，平均阳性细胞数分别是23.72 ％和59.84 ％；在DC细胞、红细胞和血小板上均不表达（0/3例）。2B8a抗原在骨髓CD34＋细胞上的阳性表达是3/3例，平均阳性细胞数39.33 ％，而在G-CSF动员的外周血CD34 细胞上的阳性表达仅1/3例，平均阳性细胞数为1.25 ％。2B8a抗原在B系细胞系Raji、SMS-SB、Nalm-6和Nall-1上的平均阳性细胞数分别为98.78 ％、98.61 ％、94.93 ％和5.68 ％；在T系细胞系Molt-3上的平均阳性细胞数为31.40 ％，而在Molt-4、JM和CCRF-CEM 细胞上不表达；在髓系细胞系U937、Meg-01、HL-60、K562、KG1a和HEL92.1.7上的平均阳性细胞数分别为67.78 ％、33.40 ％、29.70 ％、28.19 ％、16.23 ％和8.02 ％；在神经母细胞瘤细胞系SK-N-SH、KCNR、BE、LAN-1和SK-N-AS细胞以及结肠癌细胞系HR8348细胞上均不表达，而在羊膜细胞系FL细胞上呈一定的阳性表达，平均阳性细胞数为45.03％。

The split between the two groups can hardly be papered over.

这两个团体间的分歧难以掩饰。

This approach not only encourages a greater number of responses, but minimizes the likelihood of stale groupthink.

这种做法不仅鼓励了更多的反应，而且减少跟风的可能性。